Esmirtazapine

Esmirtazapine, known in development as Org 50081, is the S enantiomer of mirtazapine, isolated from the racemic antidepressant and studied in its own right ^[1][2]. Like its parent compound, it belongs to the tetracyclic class of drugs ^[1]. In its investigational formulation it was prepared as a salt of S-mirtazapine, and it has the molecular formula C17H19N3 ^[1][2]. A notable feature is its elimination half-life of roughly ten hours, considerably shorter than that of racemic mirtazapine, a property regarded as helpful for a sleep aid because it lessens lingering next-day sedation ^[1].

The compound was developed by the pharmaceutical company Organon and later carried forward by Merck after Organon was acquired ^[1]. Rather than being pursued as an antidepressant, it was investigated at low doses as a treatment for primary insomnia and for the vasomotor symptoms, or hot flashes, associated with menopause ^[1]. In 2010 Merck ended its clinical development program for esmirtazapine, citing strategic reasons, and the drug never received marketing approval ^[1].

Despite the discontinuation, several clinical studies of esmirtazapine were completed and published. An early phase 2 dose-finding study in patients with primary insomnia reported that the drug increased total sleep time and improved several other sleep measures compared with placebo, with few adverse events ^[2]. A larger phase 3 trial then followed patients with chronic insomnia over about six months and found that esmirtazapine lengthened self-reported sleep time relative to placebo, without evidence of next-day residual effects, rebound insomnia, or withdrawal on stopping; the most common side effects were sleepiness and weight gain ^[3]. The compound is one of several agents that have been explored for insomnia by acting on serotonin 5-HT2A signaling and related receptors ^[4].

Because development was halted, esmirtazapine remains an investigational compound rather than an approved medicine, and it is not marketed anywhere ^[1]. Its pharmacology closely parallels that of mirtazapine, which is itself widely prescribed as an antidepressant and is sometimes used off-label to aid sleep ^[1][4].

As concentrated mirtazapine pharmacology, expect strong sedation, and the parent drug's known effects: increased appetite and weight gain, next-day grogginess, and rarely blood-count effects. It carries the antidepressant-class cautions and should not be combined with MAOIs. It was never approved (insomnia development was discontinued), so it is handled as a research chemical; the mirtazapine track record is the closest real-world guide.